Abstract: A method for bidirectional energy exchange between an electric vehicle and a charging station. By use of a value-added service of the ISO 15118-2 communication protocol, at least one parameter and/or command concerning discharging or charging of an energy store of an energy unit of the electric vehicle are/is transferred between the energy unit and the charging station and/or between the charging station and the energy unit. The charging station carries out the discharging or charging taking into account the at least one transferred parameter and/or command. An arrangement for performing the method is also provided.

Abstract: A benchmarking service is engineered to provide computing performance metric benchmarks based on computing performance metrics provided from a variety of providers without being exposed to the underlying computing performance metrics. A homomorphic encryption scheme is used in a threshold cryptography scenario that allows aggregation of the computing performance metrics without decrypting the metrics. An independent decryption service can partially decrypt the benchmark, which can ultimately be decrypted to plaintext for use by the provider. Bitwise operations can be defined to address error problems, and the bitwise operations can be constrained to a smaller bit size to avoid proliferation of gates.

Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.

Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory bicyclic compounds, as well as to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.

Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.

Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.

Abstract: This invention provides compound having a structure of Formulas: Furthermore, methods and uses of such compounds for covalently bonding to a sugar acceptor, to form modified protein therapeutics having reduced enzymatic hydrolysis, improved biological stability or an improved pharmacokinetic property.

Abstract: This invention provides compound having a structure of Formulas: Furthermore, methods and uses of such compounds for covalently bonding to a sugar acceptor, to form modified protein therapeutics having reduced enzymatic hydrolysis, improved biological stability or an improved pharmacokinetic property.